Background: The efficacy and tolerability of the neuraminidase inhibitor zanamivir in the treatment of influenza have been established in an extensive programme of controlled clinical trials.
For example, in a network meta-analysis of mortality that included four trials of oseltamivir, peramivir, or zanamivir (Relenza) for the treatment of severe seasonal influenza, the impact on ...